Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab (Humira) in Chinese Subjects With Moderate to Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 May 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Abbott Laboratories; AbbVie
- 08 Mar 2016 Post-hoc analysis (n=425) presented at the 74th Annual Meeting of the American Academy of Dermatology.
- 18 May 2014 New trial record